The specific thyroid hormone transporter, MCT8, located on the X chromosome, has led to the identification a novel syndrome. The objective is to relate phenotype with several tissue-specific thyroid functions. A 1-year-old boy, who had severe psychological damage and low serum T4, had received l-T4 for 3 months. At admission, body length was normal but weight was low. Off therapy, serum TSH was mildly elevated, serum T4 and free T4 were low, and serum T3 and free T3 were high. Direct sequencing of the MCT8 gene revealed a single nucleotide change that resulted in a novel nonsense mutation at codon 261 (Q261X) in exon 3. Since serum T3 was high, peripheral markers of hyperthyroidism were looked for. Bone age was advanced, despite the presence of malnutrition and low T4. Serum SHBG, a marker of thyroid hormone action in liver, was markedly elevated. Markers of skeletal muscle catabolism, ammonemia and lactic acid, were found to be elevated. The phenotype of MCT 8 mutation might be explained by differences in the entry of thyroid hormones into different cells. In the presence of an inactive MCT8 transporter, the high blood T3 levels might not be enough to prevent brain damage early in life, while they seem to be able to induce a postnatal state of peripheral hyperthyroidism in other tissues, such as liver, bone and skeletal muscle.

Morreale de Escobar G, Obregon MJ, Escobar del Rey F: Is neuropsychological development related to maternal hypothyroidism or to maternal hypothyroxinemia? J Clin Endocrinol Metab 2000;85:3975–3987.
Bernal J: Action of thyroid hormone in brain. J Endocrinol Invest 2002;25:268–288.
Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR: Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002;23:38–89.
Kester MHA, Martinez de Mena R, Obregon MJ, Marinkovic D, Howatson A, Visser TJ, Hume R, Morreale de Escobar G: Iorodthyronine levels in the human developing brain: major regulatory roles of iodothyronine deiodinases in different areas. J Clin Endocrinol Metab 2004;89:3117–3128.
Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ: Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 2003;278:40128–40135.
Lafreniere RG, Carrel L, Willard HF: A novel transmembrane transporter encoded by the XPCT gene in Xq13.2. Hum Mol Genet 1994;3:1133–1139.
Friesema EC, Grueters A, Biebermann H, Krude H, von Moers A, Reeser M, Barrett TG, Mancilla EE, Svensson J, Kester MH, Kuiper GG, Balkassmi S, Uitterlinden AG, Koehrle J, Rodien P, Halestrap AP, Visser T: Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet 2004;364:1435–1437.
Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S: A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet 2004;74:168–175.
Biebermann H, Ambrugger P, Tarnow P, von Moers A, Schweizer U, Grueters A: Extended clinical phenotype, endocrine investigations and functional studies of a loss-of-function mutation A150V in the thyroid hormone specific transporter MCT8. Eur J Endocrinol 2005;153:359–366.
Schwartz CE, May MM, Carpenter NJ, Rogers RC, Martin J, Bialer MG, Ward J, Sanabria J, Marsa S, Lewis JA, Echeverri R, Lubs HA, Voeller K, Simensen RJ, Stevenson RE: Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene. Am J Hum Genet 2005;77:41–53.
Maranduba CM, Friesema EC, Kok F, Kester MH, Jansen J, Sertie AL, Passos Bueno MR, Visser TJ: Decreased cellular T3 uptake and metabolism in Allan-Herndon-Dudley syndrome (AHDS) due to a novel mutation in the MCT8 thyroid hormone transporter. J Med Genet 2006;43:457–460.
Brockmann K, Dumitrescu AM, Best TT, Hanefeld F, Refetoff S: X-linked paroxysmal dyskinesia and severe global retardation caused by defective MCT8 gene. J Neurol 2005;252:663–666.
Kakinuma H, Itoh M, Takahashi H: A novel mutation in the monocarboxylate transporter 8 gene in a boy with putamen lesions and low free T4 levels in cerebrospinal fluid. J Pediatr 2005;147:552–554.
Jansen J, Friesema EC, Milici C, Visser TJ: Thyroid hormone transporters in health and disease. Thyroid 2005;15:757–768.
Heuer H, Maier MK, Iden S, Mittag J, Friesema EC, Visser TJ, Bauer K: The monocarboxylate transporter 8 linked to human psychomotor retardation is highly expressed in thyroid hormone-sensitive neuron populations. Endocrinology 2005;146:1701–1706.
Hennemann G, Docter R, Friesema ECH, De Jong M, Krening EP, Visser TJ: Plasma membrane transport of thyroid hormone and its role in thyroid hormone metabolism and bioavailability. Endocr Rev 2001;22:451–476.
Hampl R, Kancheva R, Hill M, Bičíková M, Vondra K: Interpretation of sex hormone-binding globulin levels in thyroid disorders. Thyroid 2003;13:755–760.
Crowe TC, Cowen NL, Loidl NM, Topliss DJ, Stockigt JR, Barlow JW: Down regulation of thyroxine-binding globulin messenger ribonucleic acid by 3,5,3′-triiodothyronine in human hepatoma cells. J Clin Endocrinol Metab 1995;80:2233–2237.
Brown JG, Millward DJ: Dose response of protein turnover in rat skeletal muscle to triiodothyronine treatment. Biochim Biophys Acta 1983;757:182–190.
Doi J, Ohtsubo A, Ohtsuka A, Hayashi K: Triiodothyronine but not thyroxine accelerates myofibrillar proteolysis via ATP production in cultured muscle cells. Biosci Biotechnol Biochem 2003;67:2451–2454.
Fukui H, Taniguchi SI, Ueta Y, Yoshida A, Ohtahara A, Hisatome I, Shigemasa C: Enhanced activity of the purine nucleotide cycle of the exercising muscle in patients with hyperthyroidism. J Clin Endocrinol Metab 2001;86:2205–2210.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.